 |
|
Possible Effectiveness of Clarithromycin and Rifabutin for Cryptosporidiosis Chemoprophylaxis in HIV Disease
Scott D. Holmberg, MD, MPH;
Anne C. Moorman, BSN, MPH;
Jennifer C. Von Bargen;
Frank J. Palella, MD;
Mark O. Loveless, MD;
Douglas J. Ward, MD;
Thomas R. Navin, MD;
for the HIV Outpatient Study (HOPS) Investigators
JAMA. 1998;279:384-386.
Context.— Cryptosporidium parvum infection, a common cause of diarrhea in persons infected with the human immunodeficiency virus (HIV), is difficult to treat or prevent.
Objective.— To evaluate relative rates of cryptosporidiosis in HIV-infected patients who were either receiving or not receiving chemoprophylaxis or treatment for Mycobacterium avium complex.
Design.— Analysis of prospectively collected data from HIV-infected patients' visits to their physicians since 1992.
Setting.— Ten (8 private, 2 publicly funded) HIV clinics in 9 US cities.
Patients.— A total of 1019 HIV-infected patients with CD4+ cell counts less than 0.075x109/L.
Main Outcome Measures.— Incidence of clinical cryptosporidiosis during treatment with clarithromycin, rifabutin, and azithromycin.
Results.— Five of the 312 patients reportedly taking clarithromycin developed cryptosporidiosis vs 30 of the 707 patients not taking clarithromycin (relative hazard [RH], 0.25 [95% confidence interval (CI), 0.10-0.67]; P =.004).Two of the 214 patients taking rifabutin developed cryptosporidiosis vs 33 of the 805 not taking rifabutin (RH, 0.15 [95% CI, 0.04-0.62]; P=.01). Prophylactic efficacy of either drug was 75% or greater. No protective effect was seen in the 54 patients reportedly taking azithromycin (RH, 1.48 [95% CI, 0.44-5.04]; P=.46).
Conclusions.— Clarithromycin and rifabutin were highly protective against development of cryptosporidiosis in immune-suppressed HIV-infected persons in this analysis; further study is warranted.
From the Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention (Dr Holmberg and Mss Moorman and Von Bargen), and the Division of Parasitic Diseases, National Center for Infectious Diseases (Dr Navin), Centers for Disease Control and Prevention, Atlanta, Ga; Northwestern University Medical School, Chicago, Ill (Dr Palella); and Oregon Health Sciences University, Portland (Dr Loveless). Dr Ward is in private practice in Washington, DC.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Guidelines for Preventing Opportunistic Infections among HIV-Infected Persons--2002: Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America
Masur et al.
ANN INTERN MED 2002;137:435-478.
ABSTRACT
| FULL TEXT
Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline
Cirioni et al.
J Antimicrob Chemother 2000;46:577-582.
ABSTRACT
| FULL TEXT
Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture
Giacometti et al.
J Antimicrob Chemother 2000;45:453-456.
ABSTRACT
| FULL TEXT
1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus
USPHS/IDSA Prevention of Opportunistic Infections
ANN INTERN MED 1999;131:873-908.
FULL TEXT
In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii
Cirioni et al.
J Antimicrob Chemother 1999;44:653-659.
ABSTRACT
| FULL TEXT
New Insights into Human Cryptosporidiosis
Clark
Clin. Microbiol. Rev. 1999;12:554-563.
ABSTRACT
| FULL TEXT
Does MAC Prophylaxis Prevent Cryptosporidiosis?
JWatch Infect. Diseases 1998;1998:10-10.
FULL TEXT
|
